BioMedPartners raise CHF75m fund

Breaking News

Brexit – Implications For the Pharma Industry in Ireland The UK’s referendum decision to leave the EU in May 2016 undoubtedly sent shockwaves throughout Europe. European countries are still struggling to interpret what ‘Brexit’ will mean for them. Ireland,...
EMA to Work With Stakeholders to Improve Product Information For EU Medicines The European Medicines Agency (EMA) has published an action plan to improve the product information (PI) for EU medicines, an information package for patients and healthcare professionals that accompanies every single medicine authorised in...
Diaceutics Wins at Export Industry Awards Diaceutics, the Irish data insights and solutions company helping patients receive potentially lifesaving medicine through better testing, won the Small & Emerging Exporter of the Year Award at the recent Export...
Brexit – Key Issues For the Pharmaceutical Industry Brexit – the stark reality is that the UK’s EU membership and the application of all EU legislation in the UK ends automatically at midnight on 30th March 2019! Current understanding...
European Commission Diagnoses the State of Health in the EU Only by rethinking our health systems can we ensure that they remain fit-for-purpose and provide patient-centred care. This is what the 28 Country Health Profiles recently published by the Commission,...

BioMedPartners raise CHF75m fund

February 17

12:56 2017

Print This Article Share it With Friends

Basel-based BioMedPartners announes the first round of BioMedInvest III, its third equity venture capital fund at CHF75m. Up to 16 private Swiss, German and EU early-to-midstage ventures might be selected in the first closing by Q1/2018.

“We are delighted that the continued success of BioMedInvest convinced many of the major investors of the previous funds to commit also to BioMedInvest III. Among these are the European Investment Fund (EIF) on behalf of the ERP-EIF Dachfonds as cornerstone investor, and the Berner Kantonalbank, BEKB. In addition we could gain several important new private investors.” says Dr. Markus Hosang, General Partner at BioMedPartners.

„This is a major milestone for the future of the Swiss Life Science Cluster”, said Thomas Moeller, General Partner at BioMedPartners. “The expertise and successful investment track record that the BioMedPartners team brings to the table will enable it to translate innovative science into new companies, products and economic benefit and future growth,“ said Andreas Wallnöfer, formed Head of Clinical Research & Exploratory Development at F. Hoffmann- La- Roche AG, who now has become Partner at BioMedPartners.

BioMedPartners’ BioMedInvest III, which has a target size of CHF120-150m, is not the only life sciences vertical coming up at the global life science hub Basel. BaselArea.swiss has announced it will officially launch another life sciences accelerator termed BaseLaunch in February. The accelerator, said to be supported by several Big Pharma partners, will offer full-range support for ground breaking healthcare innovations that serve unmet medical need at the global life science hub.

According to the 2016 EU Industrial R&D Investment Scoreboard, the two Basel-based companies Novartis and Roche invest more in research and development than all other international pharmaceutical companies.

About Author

Scroll Back To Top More Articles From Author

colin

Scroll Back To Top

Biopharma Business